Abu Dhabi’s Mubadala Investment Company has established Mubadala Bio, a new life sciences subsidiary, to enhance pharmaceutical manufacturing and distribution capabilities across the UAE and internationally.
Mubadala Bio’s operations encompass 10 facilities in Asia, Africa, and Europe, with six in the UAE. Collectively, these facilities cover 110,000 square metres and have an annual production capacity exceeding 2.5 billion tablets and capsules, along with 120 million intravenous and injectable units. The company distributes over 10,000 medical products to more than 100 countries.
The company’s focus includes key therapeutic areas addressing global health needs, supporting the full continuum of care from prevention and diagnosis to treatment and supportive care. Mubadala Bio aims to strengthen national drug security, support economic diversification, and contribute to developing a knowledge-based economy in the UAE.
Mubadala Bio plans to establish strategic partnerships with global life sciences firms and academic institutions to accelerate biopharma innovation, enhance local manufacturing, and develop talent. The company will be formally introduced at the “Make it in the Emirates 2025” event, showcasing the UAE’s capabilities in the life sciences industry.
